Monuril: Uses, Dosage & Side Effects

What Is Monuril and What Is It Used For?

Monuril contains fosfomycin trometamol, a broad-spectrum bactericidal antibiotic that belongs to the phosphonic acid derivative class. Fosfomycin was originally discovered in 1969 from cultures of Streptomyces fradiae and has been used in clinical practice in Europe for decades. The trometamol salt formulation (also known as fosfomycin tromethamine in North America) was specifically developed for oral use and offers improved gastrointestinal absorption compared to earlier calcium salt formulations.

The drug works through a unique mechanism of action that is not shared by any other antibiotic class. Fosfomycin inhibits the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the very first committed step in peptidoglycan biosynthesis. Peptidoglycan is the structural polymer that gives bacterial cell walls their rigidity and strength. By blocking MurA, fosfomycin prevents the formation of N-acetylmuramic acid (a key building block of peptidoglycan), ultimately leading to weakened cell walls, osmotic instability, cell lysis, and bacterial death. Because this target is distinct from those of beta-lactams, fluoroquinolones, aminoglycosides, and all other antibiotic classes, cross-resistance is uncommon.

Fosfomycin trometamol is rapidly absorbed after oral administration, with a bioavailability of approximately 33–37%. Peak plasma concentrations are reached within 2–2.5 hours of ingestion. The drug is not metabolized in the body and is excreted unchanged primarily through the kidneys. Importantly, fosfomycin achieves very high concentrations in the urine—typically exceeding 128 µg/mL for at least 24–48 hours after a single 3 g dose. These concentrations are well above the minimum inhibitory concentration (MIC) for most common uropathogens, which explains why a single dose is sufficient for treating uncomplicated cystitis. The elimination half-life is approximately 4–6 hours, but urinary concentrations remain therapeutically effective for considerably longer.

Monuril is indicated for the treatment of the following conditions:

• Acute uncomplicated cystitis: The primary indication for Monuril is the treatment of acute lower urinary tract infections (cystitis) in women caused by susceptible organisms. This is the most common urinary tract infection and is characterized by symptoms such as burning during urination (dysuria), frequent and urgent need to urinate, and suprapubic discomfort.
• Recurrent urinary tract infections (prophylaxis): In women with recurrent UTIs (defined as three or more episodes per year), Monuril may be prescribed as intermittent prophylaxis, typically one sachet every 10 days for 3–6 months. Clinical studies have demonstrated significant reductions in recurrence rates with this approach.
• Perioperative prophylaxis: Monuril is sometimes used for prophylaxis against urinary tract infections before urological procedures, including transrectal prostate biopsy and urodynamic studies, where the risk of bacteriuria and subsequent infection is elevated.
• Asymptomatic bacteriuria in pregnancy: Some guidelines support the use of fosfomycin trometamol for treating asymptomatic bacteriuria in pregnant women, a condition that carries a risk of progression to pyelonephritis if left untreated.

Fosfomycin has broad-spectrum activity against both Gram-positive and Gram-negative bacteria commonly associated with urinary tract infections. It is particularly effective against Escherichia coli (including many extended-spectrum beta-lactamase [ESBL]-producing strains), Enterococcus faecalis, Citrobacter species, Klebsiella pneumoniae, and Proteus mirabilis. Its activity against Pseudomonas aeruginosa, Staphylococcus saprophyticus, and Serratia marcescens is more variable, and susceptibility testing should be performed when these organisms are suspected.

The European Association of Urology (EAU) and the Infectious Diseases Society of America (IDSA) both recommend fosfomycin trometamol as a first-line treatment option for uncomplicated cystitis. This recommendation reflects its high clinical efficacy, favorable side effect profile, convenience of single-dose administration, and importantly, its minimal impact on the vaginal and intestinal microbiome. Unlike fluoroquinolones and broad-spectrum cephalosporins, fosfomycin has a low propensity to select for antibiotic-resistant organisms and has minimal collateral damage to normal bacterial flora. Fosfomycin is also included on the WHO Model List of Essential Medicines.

What Should You Know Before Taking Monuril?

Before starting treatment with Monuril, it is essential to discuss your complete medical history with your healthcare provider. While fosfomycin trometamol has an excellent safety profile and relatively few contraindications compared to many other antibiotics, certain conditions and situations require careful consideration. Your doctor needs to assess whether Monuril is the most appropriate treatment for your specific situation and ensure there are no factors that might reduce its effectiveness or increase the risk of adverse effects.

Contraindications

Monuril should not be used in the following situations:

• Hypersensitivity: Do not take Monuril if you have a known allergy to fosfomycin trometamol or any of the other ingredients in the formulation (including sucrose, saccharin, and flavorings). Although allergic reactions to fosfomycin are rare, they can include skin rash, itching, swelling of the face or throat, and in extremely rare cases, anaphylaxis.
• Severe renal impairment: Monuril should not be used in patients with severe kidney disease (creatinine clearance below 10 mL/min or patients on hemodialysis). Because fosfomycin is excreted unchanged through the kidneys and relies on achieving high urinary concentrations for its therapeutic effect, severely impaired renal function may prevent adequate drug levels from being reached in the urine.
• Children under 12 years of age: The oral granule formulation of fosfomycin trometamol (Monuril 3 g) is not recommended for children under 12 years. Pediatric formulations at lower doses may be available in some countries for children with recurrent UTIs, but this should be determined by a pediatrician.

Warnings and Precautions

Special care should be taken in the following circumstances:

• Moderate renal impairment: In patients with moderate kidney disease (creatinine clearance 10–80 mL/min), Monuril can generally be used, but urinary drug concentrations may be lower and the duration of effective urinary levels may be shorter. Your doctor may monitor your response more closely.
• Diabetes: Monuril granules contain sucrose. Patients with diabetes mellitus should be aware of this and factor it into their carbohydrate management. Each sachet contains approximately 2.1 g of sucrose (the exact amount varies by manufacturer).
• Fructose intolerance: Due to the sucrose content, Monuril should not be used in patients with hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.
• Diarrhea: As with all antibiotics, fosfomycin may cause antibiotic-associated diarrhea. In rare cases, this can progress to pseudomembranous colitis caused by Clostridioides difficile. If severe or persistent diarrhea develops during or after treatment, contact your doctor.
• Persistent symptoms: If symptoms do not improve within 2–3 days after taking Monuril, consult your healthcare provider. The infection may be caused by a resistant organism, or the diagnosis may need to be reconsidered.

Pregnancy and Breastfeeding

The safety of fosfomycin trometamol during pregnancy has been evaluated in several clinical studies and post-marketing surveillance data. Animal reproduction studies have not demonstrated evidence of teratogenicity or adverse effects on fetal development. Limited human data from observational studies and case reports suggest that fosfomycin does not increase the risk of congenital malformations or adverse pregnancy outcomes. The European Association of Urology (EAU) guidelines include fosfomycin trometamol as an option for treating UTIs and asymptomatic bacteriuria in pregnant women.

However, fosfomycin does cross the placenta, and as with all medications during pregnancy, it should only be used when the potential benefit justifies the potential risk to the fetus. Urinary tract infections during pregnancy carry significant risks including pyelonephritis, preterm labor, and low birth weight, so treatment when indicated is important. Your obstetrician or midwife should make the prescribing decision based on your individual circumstances.

Fosfomycin is excreted in breast milk in small quantities. The concentrations found in breast milk are generally very low and are unlikely to cause adverse effects in the breastfed infant. The single-dose nature of Monuril further limits the duration of infant exposure. Most international guidelines consider fosfomycin compatible with breastfeeding, but you should inform your doctor if you are breastfeeding so that the risk-benefit assessment can be properly made.

How Does Monuril Interact with Other Drugs?

One of the advantages of fosfomycin trometamol is its relatively low potential for drug interactions. Fosfomycin is not metabolized by cytochrome P450 enzymes, it does not induce or inhibit hepatic drug-metabolizing enzymes, and it has minimal protein binding (approximately 0%). These pharmacokinetic characteristics mean that many of the drug interaction mechanisms that apply to other antibiotics are not relevant for Monuril. However, there are still several important interactions that patients and prescribers should be aware of.

The absorption of fosfomycin from the gastrointestinal tract can be significantly affected by drugs that alter gastric emptying or gastrointestinal motility. When food or certain medications are present in the stomach, they can form complexes with fosfomycin or speed its transit through the stomach, reducing the amount of drug that is absorbed. This is the primary basis for the recommendation to take Monuril on an empty stomach.

Major Interactions

The most clinically significant drug interaction with Monuril involves metoclopramide, an anti-nausea and prokinetic medication commonly used to treat nausea, vomiting, and gastroparesis. Metoclopramide accelerates gastric emptying and increases gastrointestinal motility, which reduces the time fosfomycin spends in the upper gastrointestinal tract where absorption primarily occurs. Studies have shown that concurrent administration of metoclopramide can reduce both the peak serum concentration (Cmax) and the overall absorption (AUC) of fosfomycin by approximately 25–30%. This reduction in absorption may lead to lower urinary concentrations of the drug and potentially reduced clinical efficacy.

If you are taking metoclopramide for any reason, inform your doctor before being prescribed Monuril. The metoclopramide should ideally be withheld for at least 24 hours before and after taking Monuril. If both medications are deemed necessary, your doctor may consider an alternative anti-emetic or an alternative antibiotic for your urinary tract infection.

Minor Interactions

Calcium-containing supplements and antacids containing calcium or magnesium can potentially form insoluble chelation complexes with fosfomycin in the gastrointestinal tract, reducing its bioavailability. While this interaction is considered minor and has not been extensively studied in clinical trials, it is prudent to separate the administration of Monuril from calcium or magnesium-containing products by at least 2 hours. This applies to calcium carbonate supplements, combined calcium and vitamin D preparations, and antacids such as magnesium hydroxide or aluminum-magnesium combinations.

Food can also reduce the absorption of fosfomycin trometamol. When taken with a high-fat meal, the Cmax of fosfomycin can be reduced by up to 30–40%, and the time to reach peak concentration is delayed. While urinary concentrations may still remain above therapeutic thresholds in many patients, taking Monuril on an empty stomach provides the most reliable and consistent drug levels. The standard recommendation is to take the sachet at least 2–3 hours before or after a meal.

What Is the Correct Dosage of Monuril?

One of Monuril's most distinctive features is its single-dose administration. While most antibiotics for urinary tract infections require multiple doses over 3–7 days, Monuril achieves therapeutic urinary concentrations that persist for 24–48 hours from a single oral dose. This is possible because of the pharmacokinetic properties of fosfomycin trometamol: it achieves high peak urinary concentrations and maintains levels above the MIC for most uropathogens for an extended period. The convenience of single-dose therapy is a major advantage in terms of patient adherence, as there is no risk of forgetting subsequent doses or discontinuing treatment prematurely.

Adults

For optimal absorption and efficacy, Monuril should be taken on an empty stomach, at least 2–3 hours before or after eating. The ideal time to take the medication is in the evening before bedtime, after emptying the bladder. This timing maximizes the contact time between the antibiotic and the bacteria in the urinary tract, as urine production is typically lower during sleep and the drug remains concentrated in the bladder for longer. The solution should be freshly prepared each time and consumed immediately after preparation.

Children

Elderly

No specific dose adjustment is required for elderly patients with normal kidney function. However, age-related decline in renal function is common and should be considered. In elderly patients with moderate renal impairment (creatinine clearance 10–80 mL/min), the standard 3 g dose can generally be used, though urinary drug concentrations may be somewhat lower. In patients with severe renal impairment (creatinine clearance below 10 mL/min), Monuril should not be used as adequate urinary drug levels may not be achieved.

Elderly patients may also be at higher risk of complicated urinary tract infections due to comorbidities, catheterization, or structural abnormalities of the urinary tract. In such cases, Monuril may not be the most appropriate choice, and a broader-spectrum or longer-course antibiotic regimen may be needed. A thorough clinical assessment by the prescribing physician is essential.

Missed Dose

Because Monuril is a single-dose treatment, the concept of a missed dose does not apply in the same way as with multi-dose antibiotics. If you forget to take Monuril on the intended evening, take it as soon as you remember, following the same instructions (on an empty stomach, after emptying the bladder). If you have already started eating or it is close to a mealtime, wait at least 2–3 hours after eating before taking the sachet.

If you vomit within 1–2 hours of taking Monuril, contact your healthcare provider for advice. Depending on the circumstances, a second dose may be recommended, as a significant portion of the drug may not have been absorbed.

Overdose

Due to the single-dose formulation and the fact that each sachet contains only 3 g of active ingredient, overdose with Monuril is uncommon. In the event of accidental ingestion of more than one sachet, the most likely effects are an increase in gastrointestinal side effects, including diarrhea, nausea, vomiting, and abdominal pain. There is no specific antidote for fosfomycin overdose. Management is supportive and symptomatic, including fluid replacement to prevent dehydration from diarrhea or vomiting. Forced diuresis can accelerate urinary excretion of fosfomycin. In cases of significant overdose, contact a poison control center or seek medical attention.

What Are the Side Effects of Monuril?

Monuril is generally well tolerated, and its single-dose administration inherently limits the duration and severity of any adverse effects. Clinical trials and post-marketing surveillance data from decades of use in Europe have established a well-characterized safety profile. Most side effects are mild to moderate in severity and resolve spontaneously without requiring treatment. The most frequently reported adverse effects are gastrointestinal in nature, reflecting the antibiotic's passage through the digestive tract and its transient effect on the gut microbiome.

It is important to distinguish between common, expected side effects and those that may indicate a more serious adverse reaction requiring medical attention. The frequency categories below follow the standard pharmacological classification system used by the European Medicines Agency (EMA) and are based on data from controlled clinical trials and post-marketing surveillance.

Diarrhea is the most commonly reported side effect, occurring in approximately 4–9% of patients in clinical trials. The diarrhea associated with Monuril is typically mild, self-limiting, and resolves within 1–2 days. It is thought to result from the direct effect of fosfomycin on the intestinal microbiome. In most cases, no specific treatment is required beyond maintaining adequate fluid intake. If diarrhea is severe, persistent (lasting more than 3 days), or accompanied by blood or mucus in the stool, medical evaluation is recommended to rule out Clostridioides difficile infection.

Nausea and headache are the next most commonly reported side effects, each occurring in approximately 1–4% of patients. These symptoms are generally mild and transient. Taking Monuril at bedtime can help minimize the impact of nausea, as many patients sleep through the peak of any gastrointestinal discomfort.

Vaginal candidiasis (yeast infection) can occur as with any antibiotic, particularly in women predisposed to vaginal yeast infections. However, because Monuril is a single-dose treatment with a relatively narrow spectrum of activity, the risk is lower than with broad-spectrum antibiotics given over multiple days. If you develop symptoms of vaginal yeast infection (itching, discharge, irritation) after taking Monuril, over-the-counter antifungal treatments are usually effective, or consult your doctor or pharmacist.

How Should You Store Monuril?

Proper storage of Monuril is important to ensure the medication remains effective and safe to use. Fosfomycin trometamol granules are hygroscopic, meaning they readily absorb moisture from the environment, which can affect the quality and potency of the medication.

Monuril should be stored at room temperature, generally below 25–30°C (77–86°F), depending on the specific manufacturer's recommendations. Keep the sachets in their original packaging until the time of use to protect them from moisture and light. Do not store the medication in a bathroom or kitchen where humidity levels tend to be high. Keep Monuril and all medications out of the reach and sight of children.

Once dissolved in water, the fosfomycin solution should be consumed immediately. Do not prepare the solution in advance and store it for later use, as the stability of fosfomycin in aqueous solution is limited and degradation may occur over time. If you notice that the granules are clumped, discolored, or have an unusual appearance, do not use the sachet and consult your pharmacist.

Do not use Monuril after the expiry date printed on the sachet and outer carton. The expiry date refers to the last day of the month indicated. If the product has expired, return it to your pharmacist for proper disposal. Do not dispose of medications in household waste or down the drain unless instructed to do so, as this can contaminate the environment.

What Does Monuril Contain?

Understanding the composition of Monuril is important, particularly for patients with allergies to specific excipients, those with diabetes (due to the sucrose content), or individuals with hereditary metabolic conditions affecting sugar metabolism.

Active Ingredient

Each sachet of Monuril contains 5.631 g of fosfomycin trometamol, which is equivalent to 3 g of fosfomycin. Fosfomycin trometamol is the tromethamine (trometamol) salt of fosfomycin, which was specifically formulated to improve oral bioavailability compared to the earlier calcium salt formulation. The trometamol salt is freely soluble in water, forming a clear solution when dissolved, and is rapidly absorbed from the gastrointestinal tract.

Inactive Ingredients (Excipients)

The inactive ingredients in Monuril may vary slightly depending on the manufacturer and country of origin, but typically include:

• Sucrose: Added as a sweetener to improve the taste of the oral solution. Each sachet contains approximately 2.1–2.213 g of sucrose. This is relevant for patients with diabetes mellitus, hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.
• Saccharin: A non-nutritive artificial sweetener used in combination with sucrose to enhance palatability.
• Orange or mandarin flavoring: Natural or artificial flavoring agents to give the dissolved solution a citrus taste, making it more pleasant to drink.
• Calcium hydroxide: Used as a pH adjuster in some formulations to ensure the correct acidity of the dissolved solution.

Monuril granules are white to off-white in color with a characteristic citrus odor. When dissolved in water, they form a clear to slightly opalescent solution. If you have any known allergies to food additives, flavorings, or excipients, review the full list of ingredients on the patient information leaflet included in the packaging, or ask your pharmacist for a complete excipient list specific to the brand available in your country.